Skip to content

HTG MOLECULAR DIAGNOSTICS, INC

Delisted

CIK 1169987fmd_1B4QRT68AXKBHRCD8JZ8Z0VPK5Manufacturing · Laboratory Analytical InstrumentsTemplate: Standard

Coverage: Jan 01, 2014 to Mar 31, 2023, 37 periods

Loading
Open Financials

HTG MOLECULAR DIAGNOSTICS, INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022FY2021ChangeSource
Revenue$6.4 million$8.9 million-28.5%10-K 2023-03-30 · proof
Gross profit$1.8 million$4.8 million-62.7%10-K 2023-03-30 · proof
Operating income-$20.8 million-$17.8 million10-K 2023-03-30 · proof
Net income-$21.6 million-$17.1 million10-K 2023-03-30 · proof
Cash from operating activities-$18.4 million-$16.5 million10-K 2023-03-30 · proof
Free cash flow-$18.4 million-$17.2 million10-K 2023-03-30 · proof
Total assets$17.8 million$30.5 million-41.6%10-K 2023-03-30 · proof
Total liabilities$12.4 million$20.1 million-38.3%10-K 2023-03-30 · proof
Cash and cash equivalents$12.2 million$9.6 million+27.2%10-K 2023-03-30 · proof
What was HTG MOLECULAR DIAGNOSTICS, INC's revenue in fiscal 2022?
HTG MOLECULAR DIAGNOSTICS, INC reported revenue of $6.4 million for fiscal 2022 (the year ended Dec 31, 2022), against $8.9 million the year before (-28.5%). Source: the 10-K filed with the SEC on Mar 30, 2023. SEC
What was HTG MOLECULAR DIAGNOSTICS, INC's gross profit in fiscal 2022?
HTG MOLECULAR DIAGNOSTICS, INC reported gross profit of $1.8 million for fiscal 2022 (the year ended Dec 31, 2022), against $4.8 million the year before (-62.7%). Source: the 10-K filed with the SEC on Mar 30, 2023. SEC
What was HTG MOLECULAR DIAGNOSTICS, INC's operating income in fiscal 2022?
HTG MOLECULAR DIAGNOSTICS, INC reported operating income of -$20.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$17.8 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2023. SEC
What was HTG MOLECULAR DIAGNOSTICS, INC's net income in fiscal 2022?
HTG MOLECULAR DIAGNOSTICS, INC reported net income of -$21.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$17.1 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2023. SEC
What was HTG MOLECULAR DIAGNOSTICS, INC's cash from operating activities in fiscal 2022?
HTG MOLECULAR DIAGNOSTICS, INC reported cash from operating activities of -$18.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$16.5 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2023. SEC
What was HTG MOLECULAR DIAGNOSTICS, INC's free cash flow in fiscal 2022?
HTG MOLECULAR DIAGNOSTICS, INC reported free cash flow of -$18.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$17.2 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2023. SEC
What are HTG MOLECULAR DIAGNOSTICS, INC's total assets?
As of Dec 31, 2022, HTG MOLECULAR DIAGNOSTICS, INC reported total assets of $17.8 million, against $30.5 million a year earlier (-41.6%). Source: the 10-K filed with the SEC on Mar 30, 2023. SEC
What are HTG MOLECULAR DIAGNOSTICS, INC's total liabilities?
As of Dec 31, 2022, HTG MOLECULAR DIAGNOSTICS, INC reported total liabilities of $12.4 million, against $20.1 million a year earlier (-38.3%). Source: the 10-K filed with the SEC on Mar 30, 2023. SEC
What are HTG MOLECULAR DIAGNOSTICS, INC's cash and cash equivalents?
As of Dec 31, 2022, HTG MOLECULAR DIAGNOSTICS, INC reported cash and cash equivalents of $12.2 million, against $9.6 million a year earlier (+27.2%). Source: the 10-K filed with the SEC on Mar 30, 2023. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1169987&period_type=annual&limit=5"

Information only, not investment advice.